On the recordApril 17, 2012
We have heard from many stakeholders that the provisions that were put in place have limited FDA's ability.
Source
congress.govEditor's note · Context
Burgess discusses concerns about conflict-of-interest provisions affecting FDA expertise.
Share & report
More from Michael Burgess
Jul 9, 2024
Madam Speaker, I yield myself such time as I may consume. Last night, the Rules Committee met and reported out a rule, House Resolution 1341, providing for the consideration of five measures: H.R. 8281, Safeguard American Voter Eligibility…
Apr 12, 2024
Mr. Speaker, I thank the gentleman for yielding additional time. However, one-sided pressure by the White House is not the way to ensure that end. Mr. Speaker, I urge passage of this rule from our committee, and I urge passage of the…
Mar 19, 2024
Mr. Speaker, may I inquire as to how much time is remaining. The SPEAKER pro tempore. The gentleman from Texas has 6\1/2\ minutes remaining.
Jul 9, 2024
Madam Speaker, I yield myself 1 minute to point out, and to bring us back to the discussion at hand, that we are talking about only having American citizens voting in American elections. We are talking about checking a Department of Energy…
Other voices in this conversation
